ACTUATE THERAPEUTICS, INC.
About ACTUATE THERAPEUTICS, INC.
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$22.2M
- Total assets
- $14.0M
- Market cap
- $45.0M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $22.5M
- Operating income
- -$22.5M
- Income tax
- $800
- Net income
- -$22.2M
- EPS (basic)
- $-1.06
- EPS (diluted)
- $-1.06
Balance sheet
- Total assets
- $14.0M
- Current assets
- $13.6M
- Total liabilities
- $6.1M
- Current liabilities
- $5.7M
- Shareholders’ equity
- $7.9M
Cash flow
- Operating cash flow
- -$19.2M
- Investing cash flow
- -$4.5M
- Financing cash flow
- $23.7M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $45.0M
- EPS (diluted)
- $-1.06
- Shares outstanding
- 24.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 13, 2024
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $22.2M.
- Trading 85% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review ACTUATE THERAPEUTICS, INC..
Write a review
News about ACTUATE THERAPEUTICS, INC.
News & sentiment via Polygon.io
